Search Results

Corbus Pharmaceuticals Holdings, Inc. today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a panel discussion as part of the BTIG Obesity Health Forum, to be held virtually on May 8, 2024.

Corbus Pharmaceuticals Holdings, Inc. today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the 45th Annual Goldman Sachs Global Healthcare Conference to be held June 10-13, 2024 in Miami Beach, FL.

Corbus Pharmaceuticals Holdings, Inc., announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the 2024 RBC Capital Markets Global Healthcare Conference to be held May 14-15, 2024 in New York, NY.

Corbus Pharmaceuticals Holdings, Inc., a precision oncology company with a diversified portfolio, provided a corporate update and reported financial results for the quarter ended March 31, 2024.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that an abstract providing updated data from the Phase 1, first-in-human clinical data from a dose escalation study being carried out by its partner CSPC in China with CRB-701 (SYS6002) has been accepted for presentation at the 2024 American Society of Clinical Oncology annual meeting, to be held May 31-June 4, 2024 in Chicago, IL.

Corbus Pharmaceuticals Holdings, Inc. today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a panel discussion at BMO Capital Markets Inaugural BMO Obesity Summit to be held on March 20, 2024 in New York City, NY.